Avenir® Cemented Hip Stem - PMCF

NCT03396224 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-11-25

No results posted yet for this study

Summary

The objective of this post-market clinical follow-up study is to confirm the safety and performance of the Avenir® Cemented Hip stem when used in primary total hip arthroplasty.

Conditions

  • Primary Osteoarthritis
  • Post-Traumatic Osteoarthritis of Hip
  • Femoral Neck Fractures
  • Femoral Head Necrosis
  • Sequelae From Previous Hip Surgery
  • Osteotomies
  • Congenital Hip Dysplasia

Sponsors & Collaborators

  • Zimmer Biomet

    lead INDUSTRY

Principal Investigators

  • Hassan Achakri · Zimmer Biomet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-18
Primary Completion
2030-11-30
Completion
2030-11-30

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03396224 on ClinicalTrials.gov